Gerda

Gerda is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare neuromuscular diseases, with a primary focus on GNE myopathy (also known as Hereditary Inclusion Body Myopathy). The company's lead program involves the development of aceneuramic acid (sialic acid) in an extended-release formulation designed to address the underlying biochemical deficiency in patients with GNE mutations. Gerda has historically collaborated with major rare disease players, most notably Ultragenyx Pharmaceutical, to advance its lead candidate through late-stage clinical trials. The company was founded by Dr. Daniel Darvish, a leading expert and advocate in the GNE myopathy field, to translate academic research into viable commercial treatments for ultra-orphan indications.